Scitech Biosciences (CTKB) Q2 2026: U.S. Revenue Jumps 18% as Installed Base Expansion Drives Recurring Growth
Scitech Biosciences delivered solid Q2 growth, propelled by strong U.S. and China demand and a rising installed base fueling recurring revenue expansion. New product launches, including the Borealis 60-color cytometer, reinforced the company’s technology leadership and market share gains in high-end research. Management’s guidance raise reflects confidence in sales momentum and deeper customer engagement, but EMEA headwinds and cost inflation remain watchpoints for the back half.
Summary
- Installed Base Expansion Accelerates Recurring Revenue: Service and reagent lines now account for a larger share of total sales.
- Technology Leadership Evident in New Launches: Borealis and Aurora Evo automation drive differentiation and customer adoption.
- EMEA Weakness and Cost Pressures Persist: Regional budget constraints and rising expenses offset gains in core markets.
Business Overview
Scitech Biosciences develops and sells advanced flow cytometry instruments, reagents, and software for cell analysis in research, clinical, and biopharma settings. Revenue streams include instrument sales, consumables (reagents), and services, with a growing focus on recurring revenue from service contracts and reagent usage. The business is geographically diversified, with major segments in the U.S., EMEA (Europe, Middle East, Africa), China, and broader APAC (Asia-Pacific) regions. Key customer groups include academic, government, and biopharma organizations.
Performance Analysis
Scitech posted 6% top-line growth in Q2, driven by a robust 18% increase in U.S. sales and double-digit gains in China. The installed base grew by 142 units to 3,933, supporting an 8% year-over-year rise in recurring revenue (reagents and services), which now represents 35% of trailing 12-month sales—up from 32% a year ago. Service revenue advanced 10%, reflecting high utilization rates and the expanding fleet of instruments in the field.
While the U.S. and China were bright spots, EMEA revenue fell 8% and instrument sales in the region dropped 10%, as government R&D funding remained pressured by shifting priorities. APAC, excluding China, was flat, with normal fluctuations in customer purchasing after a stronger Q1. Gross margin benefited from a one-time $2.8 million tariff refund, but underlying margin excluding this was up modestly year-over-year, aided by lower material costs in services. However, operating expenses rose 15%, led by higher R&D, sales and marketing, and legal costs, driving a wider net loss and a negative adjusted EBITDA for the quarter.
- Recurring Revenue Momentum: Service and reagents now comprise a larger share of total revenue, reinforcing business resilience and visibility.
- Product Mix Shift: High-end instruments, notably the Aurora Evo and Borealis launches, drove mid-teens growth in the core portfolio.
- Regional Divergence: U.S. and China delivered strong growth, while EMEA softness and APAC fluctuations offset gains.
Cash flow remained neutral, with a $262 million cash balance providing flexibility to invest in growth and innovation. Management raised the low end of full-year guidance, signaling continued confidence in demand and execution.
Executive Commentary
"Our recurring revenue base now represents 35% of last 12 months' revenue, with service revenue delivering consistent double-digit year-over-year growth, and our related business remaining well-positioned to expand."
Wenbin Jiang, Chief Executive Officer
"We anticipate adjusted EBITDA to improve in the second half as revenue increases with our normal seasonal pattern and operating expense growth moderates. For the full year 2026, we expect to deliver around break-even adjusted EBITDA."
Bill McCombe, Chief Financial Officer
Strategic Positioning
1. Recurring Revenue Transformation
Scitech’s installed base expansion is structurally increasing recurring revenue share, as service and consumables attach rates rise. This shift supports more predictable cash flows and underpins the company’s ability to weather geographic or macro volatility.
2. Technology Leadership and Product Differentiation
The launch of Borealis, a 60-color, 7-laser cytometer, and the Aurora Evo automation suite, positions Scitech as a technology leader in high-end cell analysis. These innovations expand addressable applications, particularly for biopharma and automation-driven labs, and reinforce the company’s value proposition versus conventional systems.
3. Geographic and Segment Diversification
Scitech’s double-digit U.S. and China growth offset EMEA weakness, demonstrating the benefit of a diversified global footprint. While EMEA remains challenged by budget constraints, management continues to invest in sales and marketing to capture share as funding environments recover.
4. Strategic Reorganization for Customer Alignment
The transition to three customer-aligned business units (Solutions and Clinical, Research Technology, Service) is designed to sharpen focus on distinct market opportunities and optimize resource allocation. Management expects improved market penetration, especially in mid and lower-end instruments and reagents, though benefits will materialize gradually.
5. Clinical Market Penetration
Scitech’s clinical business remains small due to limited U.S. regulatory approvals, but the company is building capabilities and product offerings to expand in this under-penetrated segment over time, particularly as new panels and software drive adoption in EMEA and Asia.
Key Considerations
The quarter highlighted Scitech’s operational strengths and market leadership, but also surfaced persistent headwinds and execution dependencies. Investors should weigh these factors in the context of the company’s evolving business model and competitive landscape.
Key Considerations:
- Recurring Revenue Expansion: The shift toward service and consumables is strengthening revenue durability and margin profile.
- Innovation as a Differentiator: New high-parameter instruments and automation capabilities are boosting competitive positioning and customer engagement.
- Regional Imbalances Persist: EMEA and parts of APAC remain pressured, though China and U.S. are offsetting with robust growth.
- Cost Structure Volatility: Elevated legal and personnel costs, along with one-time items, are weighing on margins and profitability.
- Execution on Reorganization: The operational realignment is a multi-quarter process, with benefits expected to accrue gradually rather than immediately.
Risks
EMEA revenue contraction and government budget constraints present ongoing headwinds, with potential for further volatility if macro or geopolitical factors worsen. Rising operating expenses, including legal and severance costs, could pressure margins if not offset by top-line outperformance. The clinical segment’s growth is gated by regulatory approvals, especially in the U.S., while competitive intensity in high-end instruments and automation may erode pricing or share if innovation leadership slips.
Forward Outlook
For Q3 2026, Scitech guided to:
- Revenue growth accelerating in Q4 versus Q3, consistent with historical seasonality
- Adjusted EBITDA improvement as operating expense growth moderates
For full-year 2026, management raised the low end of revenue guidance to $207 million to $212 million, increasing the midpoint by $1 million.
- Break-even adjusted EBITDA for the year, assuming no major currency shifts
Management highlighted several factors that will shape the back half:
- Continued U.S. and China strength expected to offset EMEA and APAC fluctuations
- Benefits from the new organizational structure to begin accruing, but with a lag
Takeaways
Scitech’s Q2 results reinforce the company’s position as a technology and installed base leader, with recurring revenue and innovation driving resilience amid regional and cost headwinds.
- Installed Base and Recurring Revenue: Expansion of the service and reagent base is structurally improving revenue quality and customer stickiness, supporting future margin improvement.
- Innovation Pipeline Delivers: Borealis and Aurora Evo launches are strengthening Scitech’s competitive moat in high-end research and automation-centric labs.
- Watch EMEA and Cost Discipline: Investors should monitor EMEA recovery and management’s ability to control operating expense growth as topline gains materialize.
Conclusion
Scitech Biosciences delivered another quarter of steady growth, fueled by U.S. and China demand and a rising recurring revenue mix. The company’s innovation engine and organizational realignment provide levers for future outperformance, though regional imbalances and expense management will remain key focus areas for investors in coming quarters.
Industry Read-Through
Scitech’s strong U.S. and China performance, coupled with EMEA weakness, reflects a broader trend in life sciences tools where North American and Chinese demand are outpacing Europe due to funding and geopolitical dynamics. The shift to recurring revenue and high-parameter instrumentation is mirrored across the sector, as companies seek to build resilience and deepen customer engagement. Automation and cloud-enabled workflows are emerging as critical differentiators, signaling that future winners will be those who can integrate hardware, software, and services into seamless research solutions. Ongoing cost inflation and legal risks are sector-wide watchpoints, especially as innovation cycles accelerate and competitive intensity rises.